ARTICLE IN PRESS



1. Introduction

Alzheimer's disease (AD) is the most common type of de-mentia and is believed to account for approximately 50 to 70% of all cases of dementia [1]. AD is characterized by typical neuropathological changes, neurofibrillary tangles, and senile plaques, gradually spreading throughout the brain [2]. Traditionally, AD is categorized as either early-onset Alzheimer's disease (EOAD, age ≤ 65 years) or late-onset Alzheimer's disease (LOAD, age >65 years). EOAD is thought to have a faster rate of progression and shows a greater neuropathological burden than LOAD [3]. Cogni-tively, LOAD is characterized by a classic AD profile with

impaired semantic memory function as the most prominent finding whereas EOAD may present a more atypical profile with apraxia and impaired visuospatial functions [4]. Structural imaging studies have been performed to elucidate whether EOAD is AD with an earlier starting point or if EOAD should be regarded as a different nosological entity. The interpretation of these imaging studies is complicated by generally small group sizes and different methodological approaches. Although not consistent, most studies have reported a higher degree of neocortical atrophy in EOAD compared with LOAD [5-9]. Although some studies do not find a difference in hippocampal atrophy between EOAD and LOAD [9,10], most studies report more pronounced hippocampal atrophy in LOAD [5,6,8,11].

A better understanding of the structural brain changes taking place in AD and their relation to age at onset would be useful to improve inclusion criteria in future intervention studies and also for increasing the etiological/nosological

https://doi.org/10.1016/j.dadm.2018.02.001

The authors have no competing interests to report.

^{*}Corresponding author. Tel.: +46 31 3438668; Fax: +46 31 7769055.

E-mail address: carl.eckerstrom@neuro.gu.se

^{2352-8729/ © 2018} The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

2

understanding of the disease. Furthermore, as patients with
dementia diseases often undergo an incipient phase when
differential diagnostics can be difficult, information on patterns of atrophy in AD at different ages of onset will be highly valuable.

The aim of the present study is to investigate if EOAD and LOAD have different patterns of atrophy compared with healthy controls of similar age and also by direct comparison between EOAD and LOAD.

1211222. Materials

120

123 2.1. The Gothenburg MCI study

124 The Gothenburg MCI study is a clinically based longitu-125 dinal study that aims at identifying neurodegenerative, 126 vascular, and stress-related disorders before the develop-127 ment of dementia [12]. The Gothenburg MCI study is 128 129 approved by the Local Ethics Committee (diary number: 130 L091-99, 1999; T479-11, 2011). Inclusion requires subjec-131 tive and/or objective (by an informant) verifications of a pro-132 gressive cognitive impairment for more than 6 months, age 133 \geq 50 and \leq 79 years, and Mini–Mental State Examination 134 (MMSE) score >18. Exclusion criteria are acute/instable so-135 matic disease, severe psychiatric disorder, or substance 136 abuse. 137

Healthy controls were recruited from senior citizens' organizations. Controls were not included if they had subjective or objective signs of cognitive disorder as assessed
with the aforementioned procedure or fulfilled any of the
aforementioned exclusion criteria.

144 *2.2. Classification* 145

146 Patients' degree of decline was staged according to the 147 Global Deterioration Scale (GDS). GDS classification is 148 made by means of checklists and instruments for cognitive 149 symptoms [12]. The guidelines for the classification used 150 are as follows: for GDS 4 (mild dementia) participants 151 should have MMSE \leq 25, CDR sum of boxes > 1.0, I-152^{Q5} FLEX > 3, and two or more positive outcomes on variables 153 13 to 20 of STEP [13]. When the guidelines are not appli-154 cable, a consensus decision among physicians at the clinic 155 is made to determine appropriate GDS score. All patients 156 157 classified as GDS 4 were further assessed by a specially 158 trained physician for specific dementia diagnosis. Anam-159 nestic and clinical symptomatology and the presence of ce-160 rebral white matter changes determined by a modified 161 version of the Fazekas scale were taken into account in the 162 diagnostic procedure [14]. If the diagnosis cannot be unam-163 biguously determined, then it is further discussed and estab-164 lished in a clinical consensus meeting. AD is diagnosed 165 using the NINCDS-ADRDA criteria for AD [15]. For an 166 AD diagnosis, the patient must have at most only mild white 167 matter changes and predominant temporoparietal lobe 168 169 symptoms. This was done to ensure that no patients with 170 mixed dementia were classified as AD. Only patients with GDS 4 and an AD diagnosis were included in the present study. The guidelines and diagnostics are described in detail in a previous publication [12].

171 172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190 191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

2.3. The present study

The present study is a substudy of the Gothenburg MCI study. An additional inclusion criterion for all participants was a magnetic resonance imaging scan using a Siemens Symphony 1.5 T scanner available for analysis. Patients also had to be classified as GDS 4 and subsequently received an AD diagnosis according to the NINCDS-ADRDA criteria.

The total patient group (N = 145) consisted of 63 patients with AD and 94 healthy controls. Of the 63 AD patients, 24 were ≤ 65 years and classified as EOAD, and 39 were ≥ 65 years, that is, LOAD. Of the healthy controls, 25 were ≤ 65 years, and 57 were ≥ 65 years. Patients with mixed dementia or vascular dementia were not included in the study.

3. Methods

A 1.5 T scanner (Siemens Symphony, Erlangen, Germany) was used for the magnetic resonance data acquisition. FreeSurfer volumetry was performed on T1 3D IR/GR im-Q6ages (repetition time 1610 ms, echo time 2.38 ms, flip angle 15°, coronal slices, field of view 250 mm × 203 mm, slice thickness 1 mm, pixel spacing 0.49 mm × 0.49 mm, and matrix size 512 × 416).

Cerebrospinal fluid (CSF) samples were collected by lumbar puncture. CSF T-tau and amyloid β 42 levels were determined using a sandwich enzyme-linked immunosorbent assay constructed to measure T-tau or amyloid β 42 [16].

3.1. FreeSurfer

Brain volumes were measured using the automated segmentation software, FreeSurfer, version 5.3.0, which is freely available for download online [17]. The FreeSurfer analyses were performed on a computing cluster running 64 bit CentOS 6. These analyses were performed on nodes based on Supermicro X9DRT Intel E5-2670 (Sandy Bridge) running at 2.6 GHz. A few analyses were also performed using a MacPro 3.1 with 64 bit 2 GHz \times 2.8 GHz quad-core Intel Xeon processors and Mac OSX 10.8.5.

The calculation of surface volumes in FreeSurfer begins with an affine alignment to the MNI305 atlas, an intensity normalization, and removal of the skull [18,19]. Voxels are then classified as white matter or nonwhite matter by a threshold classification that is refined by some assumptions of the classification of the given voxel and its neighboring voxels [18]. Seed points in corpus callosum and the pons from the atlas alignment are then used to find two cut planes to separate the hemispheres and to remove subcortical structures [18]. A white matter surface is then generated for each hemisphere by the outer boundary of the white matter volume and some refinement based on intensities gradients [18,20]. The pial surface is then deformed outward from Download English Version:

https://daneshyari.com/en/article/8680274

Download Persian Version:

https://daneshyari.com/article/8680274

Daneshyari.com